Pnc Financial Services Group, Inc. Galectin Therapeutics Inc Transaction History

Pnc Financial Services Group, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	BUY	$1.61 - $2.31 $16,100 - $23,100	10,000 Added 21.65%	56,184 $90,000
Q3 2021 Nov 05, 2021	SELL	$2.59 - $4.15 $893 - $1,431	-345 Reduced 0.74%	46,184 $179,000
Q2 2021 Aug 06, 2021	BUY	$2.07 - $5.1 $714 - $1,759	345 Added 0.75%	46,529 $148,000
Q4 2020 Feb 12, 2021	SELL	$2.24 - $2.87 $48,796 - $62,520	-21,784 Reduced 32.05%	46,184 $103,000
Q3 2019 Nov 08, 2019	BUY	$3.0 - $4.05 $9,000 - $12,150	3,000 Added 4.62%	67,968 $249,000
Q2 2019 Aug 09, 2019	BUY	$3.61 - $5.0 $64,272 - $89,020	17,804 Added 37.75%	64,968 $0
Q3 2018 Nov 09, 2018	SELL	$3.68 - $6.93 $18,400 - $34,650	-5,000 Reduced 9.59%	47,164 $0
Q2 2018 Aug 10, 2018	BUY	$3.16 - $9.16 $3,096 - $8,976	980 Added 1.91%	52,164 $0
Q4 2017 Feb 09, 2018	BUY	$1.54 - $3.34 $78,823 - $170,954	51,184	51,184 $0

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.